Press releases | WebDisclosure

PRESS RELEASE

published on 04/08/2024 at 23:20, 2 years 3 months ago

Ur-Energy Announces Appointment of New Board Members: John Paul Pressey and Elmer W. Dyke
Ur-Energy Inc. appoints John Paul Pressey and Elmer W. Dyke as new Board members, announces retirement of James M. Franklin and W. William Boberg. Company expresses gratitude towards retiring Directors

Board Members Ur-Energy Inc. Leadership Transition Retirement Nuclear Power
PRESS RELEASE

published on 04/08/2024 at 23:15, 2 years 3 months ago

Data4Cure Announces a Late-Breaking Abstract to Be Presented at the 2024 American Association for Cancer Research Annual Meeting
Data4Cure announces the release of the Single-Cell Immune Checkpoint Inhibition Atlas at AACR 2024, facilitating insights on cancer immunotherapy. CEO highlights integration of high-throughput data for new therapies

Cancer Research Immunotherapy AACR 2024 Data4Cure Single-cell Atlas
REGULATED PRESS RELEASE

published on 04/08/2024 at 23:12, 2 years 3 months ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results and business update, highlighting progress in clinical programs and partnerships. CEO Stanislas Veillet shares insights on growth strategies and collaborations

Financial Results Biophytis Partnerships Clinical Programs Growth Strategies
REGULATED PRESS RELEASE

published on 04/08/2024 at 23:12, 2 years 3 months ago

Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités
Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités. La société publie ses résultats opérationnels et financiers pour l’exercice clos le 31 décembre 2023, mettant en avant ses avancées dans le développement de traitements pour les maladies liées à l'âge

Résultats Financiers Biophytis Développement Clinique Maladies Liées À L'âge Traitements
REGULATED PRESS RELEASE

published on 04/08/2024 at 23:10, 2 years 3 months ago

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Biophytis launches OBA Phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone), aiming to address muscle loss from obesity treatment and promising results in preclinical studies. Clinical study expected to start mid-2024 with results in 2025

Biophytis Clinical Study BIO101 OBA Phase 2 Obesity
REGULATED PRESS RELEASE

published on 04/08/2024 at 23:10, 2 years 3 months ago

Biophytis lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone)
Biophytis lance l'étude clinique de phase 2 OBA pour traiter l'obésité avec BIO101 (20-hydroxyecdysone), visant à préserver la masse musculaire. Programme ayant des résultats prometteurs, début de l'étude prévu mi-2024

Biophytis Étude Clinique BIO101 Obésité OBA
PRESS RELEASE

published on 04/08/2024 at 23:04, 2 years 3 months ago

Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités
Biophytis annonce ses résultats financiers 2023 et fait le point sur ses activités. Découvrez les principaux faits marquants et perspectives pour 2024 ainsi que les éléments financiers clés de l'année 2023

Biophytis Biotechnologie Développement Clinique Résultat Annuel Santé
PRESS RELEASE

published on 04/08/2024 at 23:04, 2 years 3 months ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results & updates business activities. Successfully developing clinical programmes & obtaining FDA approval for SARA-31 trial in sarcopenia

Biophytis FDA Approval 2023 Financial Results Clinical Programmes SARA-31 Trial
PRESS RELEASE

published on 04/08/2024 at 23:01, 2 years 3 months ago

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Biophytis annonce ses résultats financiers 2023 et lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone), confirmant son avancement dans le développement de traitements innovants

Biophytis Résultat Annuel Étude Clinique BIO101 Obésité
PRESS RELEASE

published on 04/08/2024 at 23:01, 2 years 3 months ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results & business update. Highlights: progress in clinical programmes, funding secured till 2025. Key focus on SARA, OBA, COVA, OBA, and MYODA programs

Financial Results Biophytis 2023 Funding Clinical Programmes

Published on 07/31/2026 at 01:39, 4 hours 53 minutes ago

Transition from OTCQB to Unsponsored OTC Quotation
Published on 07/30/2026 at 23:45, 6 hours 47 minutes ago

Namibia Critical Metals Announces Completion of Japan's C$23 Million Earn-In and Formation of Strategic Joint Venture Company for the Lofdal Heavy Rare Earth Project
Published on 07/30/2026 at 23:01, 7 hours 31 minutes ago

Pinetree Capital Announces Unaudited Financial Results for the Period Ended June 30, 2026 and Management Changes
Published on 07/30/2026 at 23:00, 7 hours 32 minutes ago

Eagle Plains Announces Approval of Warrant Expiry Extension
Published on 07/30/2026 at 18:52, 11 hours 40 minutes ago

First Canadian Graphite annonce des résultats de prospection de graphite à haute teneur jusqu'à 43,4 % Cg au projet Lac Guéret Sud

View all ACCESSWIRE

Published on 07/31/2026 at 00:00, 6 hours 31 minutes ago

EQS-Adhoc: VIB Vermögen AG: Agreements on the restructuring of financial liabilities of BRANICKS Group AG signed, incl. commitment for a € 60 mn financing for VIB Vermögen AG
Published on 07/30/2026 at 23:48, 6 hours 43 minutes ago

BRANICKS Group AG Reaches Comprehensive Restructuring Agreement with Its Creditors
Published on 07/30/2026 at 23:46, 6 hours 45 minutes ago

EQS-Adhoc: Branicks Group AG: BRANICKS Group AG Reaches Comprehensive Restructuring Agreement with Its Creditors
Published on 07/30/2026 at 22:05, 8 hours 27 minutes ago

Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
Published on 07/30/2026 at 22:05, 8 hours 27 minutes ago

Abivax annonce un retour positif de la FDA à l’issue de ses échanges pré-NDA concernant l’obéfazimod

View all EQS

Published on 07/30/2026 at 18:15, 12 hours 16 minutes ago

Publication of the 2026 half-year financial report
Published on 07/30/2026 at 18:15, 12 hours 16 minutes ago

Mise à disposition du rapport financier semestriel au 30 juin 2026
Published on 07/30/2026 at 18:05, 12 hours 26 minutes ago

Electricité de Strasbourg - Avis de mise à disposition de l'information financière du 1er semestre 2026
Published on 07/30/2026 at 18:01, 12 hours 30 minutes ago

First-half 2026 results
Published on 07/30/2026 at 18:01, 12 hours 30 minutes ago

Résultats du 1er semestre 2026

View all LES ECHOS COMFI WIRE

News